Was the Pfizer-Allergan merger proposal really a windfall for Ireland?
When new rules proposed by the US Treasury stopped the $160 billion Pfizer-Allergan super-inversion in early April many Americans applauded. Some grumbled about unfair tax loopholes or blamed Ireland’s 12.5% corporate tax for luring away American companies who pay up to 35% tax back home.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: